InvestorsHub Logo
Followers 31
Posts 4419
Boards Moderated 0
Alias Born 07/25/2007

Re: NY1972 post# 942

Friday, 03/19/2021 1:34:11 PM

Friday, March 19, 2021 1:34:11 PM

Post# of 977

TRIL has wasted too much time, even CRIS has developed a combo CA-4948 + ibrutinib to treat Relapsed or Refractory Hematologic Malignancies.
CD-47 space is a big leaking bubble.



Oh please, CRIS has dosed its first patient in phase 1. They aren't in phase 3. Your leaking bubble comment made me laugh. Thanks.